益肺扶正解毒法防治肺癌化疗骨髓抑制的临床观察及对Wnt/β-catenin 通路的机制影响-国际中医药研究-CSCIED科技核心评价数据库-手机版

益肺扶正解毒法防治肺癌化疗骨髓抑制的临床观察及对Wnt/β-catenin 通路的机制影响

Clinical observation of Yifei Fuzheng Jiedu method for preventing and treating chemotherapy-induced myelosuppression in lung cancer patients and its mechanistic impact on the Wnt/β-catenin pathway

ES评分 0 浏览量：212 下载量：0

全文阅读下载引用收藏

DOI	10.12208/j.ircm.20260036
刊名	国际中医药研究 International Research in Chinese Medicine
年，卷(期)	2026, 6(2)
作者	程玉峰, 郜曦, 郝庆伟, 何蕊, 怀利, 李艳彬, 夏奔, 夏友宏,
作者单位	亳州市中医院呼吸科安徽亳州;
摘要	目的本研究拟探讨益肺扶正解毒法对肺癌化疗相关骨髓抑制的干预效果，并重点研究其对WNT/β-catenin信号通路的影响。方法采用随机对照试验设计，将60例接受化疗的肺癌患者随机分为两组，对照组30例仅接受常规支持治疗，治疗组30例在常规治疗基础上联合益肺扶正饮（治法为益肺扶正解毒法）。观察两组外周血象（白细胞、血小板、血红蛋白计数）变化，并在治疗期间动态观察两组治疗前后中医证候积分、功能状态（KPS）评分；借助采用流式细胞术动态检测外周血CD34⁺造血干细胞比例，同时通过荧光定量PCR动态检测血清中Wnt3a、c-Myc的mRNA表达水平。结果与对照组相比，治疗组患者化疗后外周血象指标下降幅度更小（P<0.05），中医证候积分明显下降，KPS评分明显著提升（P<0.05）。机制分析显示，与对照组相比，治疗组干预14天后，Wnt3a、c-Myc mRNA表达及外周血CD34⁺细胞比例均接近正常水平，差异无统计学意义（P>0.05）。组内比较显示：治疗后7天，两组各指标均较治疗前明显改变（P<0.05）；治疗后14天，对照组各指标仍显著异于治疗前及治疗后7天（P<0.05），而治疗组各指标仅与治疗后7天存在显著差异（P<0.05），且两组各时间点比较差异均有统计学意义（P<0.05）。结论益肺扶正解毒法能够缓解肺癌患者化疗后骨髓抑制程度，提高机体免疫力，改善生活质量，其作用机制可能与上调 Wnt3a、c-Myc 表达，提升外周血CD34+细胞比例有关。
Abstract	Objective This prospective randomized controlled trial was designed to explore the clinical efficacy and underlying mechanism of Yifei Fuzheng Jiedu Therapy in mitigating chemotherapy-induced myelosuppression in patients with lung cancer, focusing on its regulatory effects on key molecules within the Wnt/β-catenin signaling pathway. Methods A randomized controlled trial was designed. Sixty chemotherapy-treated lung cancer patients were randomized into control (n=30) and treatment (n=30) groups. The control group received conventional supportive care only, while the treatment group was supplemented with Yifei Fuzheng Yin (therapeutic principle: YFJ therapy). Peripheral blood cell counts were evaluated pre- and post-treatment, and TCM syndrome scores and KPS scores were dynamically tracked. CD34+ hematopoietic stem cells were dynamically analyzed by flow cytometry, and Wnt3a/c-Myc mRNA expression was dynamically measured by qRT-PCR. Results Compared with the control group, patients in the treatment group had a smaller decrease in peripheral blood indicators after chemotherapy (P<0.05), a significant reduction in TCM syndrome scores, and a marked improvement in KPS scores (P<0.05).Following 14 days of intervention, Wnt3a/c-Myc mRNA expression and CD34+ cell proportion in the treatment group returned to normal levels, with no inter-group difference (P>0.05).Intra-group analysis demonstrated significant changes in all indicators at 7 days post-treatment vs baseline in both groups (P<0.05). At 14 days, control group indicators still differed from baseline and 7-day values (P<0.05), whereas treatment group indicators differed in 7-day values (P<0.05). All inter-group comparisons at each time point were significant differences(P<0.05). Conclusion Our findings indicate that YFJ herapy mitigates chemotherapy-related myelosuppression, boosts immune function, and improves quality of life in lung cancer patients. Its mechanism could involve upregulating Wnt3a/c-Myc expression and increasing peripheral blood CD34+ cell proportion.
关键词	肺癌；临床观察；WNT/β-catenin通路；骨髓抑制；益肺扶正解毒法
KeyWord	Lung cancer; Clinical observation; WNT/β-catenin pathway; Bone marrow suppression; Yifei Fuzheng Jiedu Therapy
基金项目
页码	66-74

参考文献
相关文献

[1] Sung H,FerLay J,Siegek RL,etal.GLobaL cancer statistics 2020:GLOBOCAN estimates of incidengce and mortlity world-wide for 36 cancers in 185 countries
[J].CA Cancer J CL in,2021,71(3):209-249.

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:10.3322/caac.21590.

[3] 中华人民共和国国家卫生健康委员会.原发性肺癌诊疗指南（2022年版）
[J].中国合理用药探索,2022,19(09):1-28.

[4] 中华人民共和国国家卫生委员会.原发性肺癌诊疗规范(2018年版)
[J].肿瘤综合治疗电子杂志,2019,5(3):100-120.

[5] Alberg A J, Brock M V, Ford J G, et al. Epidemiology of lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines
[J]. Chest, 2013, 143(5): e1S-e29S.

[6] 冯唐韬,张馨文,刘玲乐,等.呼出气冷凝液在呼吸系统疾病应用及研究进展
[J].中国呼吸与危重监护杂志,2025, 24(4):281-285.

[7] 中国老年保健协会肺癌专业委员会, 北京肿瘤学会肺癌专业委员会. 老年晚期肺癌内科治疗中国专家共识（2022版）
[J]. 中国肺癌杂志, 2022, 25(6): 363-384.

[8] 白莹,刘俊岑,王佳佳,等.基于Wnt/β-catenin通路探讨当归补血汤防治化疗后骨髓造血细胞衰老的机制
[J].中国中医基础医学杂志,2023,29(11):1840-1846.

[9] Sutjarit N, Ruknarong L, Tanprasertkul C, et al. Andrographolide promotes the ex vivo expansion of CD34+ hematopoietic stem cells derived from human umbilical cord blood. Sci Rep. 2025;15(1).

[10] Niu YX, Li YH, Wang J.
[Research Progress of the Wnt/β-catenin Signaling Pathway in the Regulation of Oxidative Stress and Its Impact on the Hematopoietic System --Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025;33(3): 927-930.

[11] 张泽祥,张茂福,包璇,等.中医药干预化疗后骨髓抑制相关信号通路的研究进展
[J].环球中医药,2026,19(2):363-374.

[12] 李发枝,郑玉玲,李宗铎,等. 解药毒法防治癌症化疗白细胞减少30例
[J]. 中国医药学报, 1990(6): 47-48.

[13] 邓海滨,王中奇,蔡玥娇,等.徐振晔辨治无驱动基因晚期非小细胞肺癌验案1则
[J].中医药通报,2023,22(11):64-66.

[14] 史琳,王程军,刘松林,等. 减毒增效升白汤治疗恶性肿瘤化疗所致白细胞减少症疗效观察
[J]. 北方药学,2021, 18(1): 65-66.

[15] 王羽超,许斌,李丽,等. 扶正解毒抗癌方对晚期非小细胞肺癌肺脾两虚型患者疗效及化疗后骨髓抑制的影响
[J]. 肿瘤药学,2021,11(1): 82-86.

[16] 粟薇,梁建,刘宇,等.Wnt3a在相关肿瘤中的作用
[J].检验医学与临床,2024,21(13):1977-1980.

[17] 徐霞,张艺森,雷瑞瑞,等.毛蕊花糖苷通过Wnt/β-catenin信号通路对新生大鼠缺血缺氧性脑损伤的改善作用
[J].中华中医药杂志,2023,38(10):4897-4901.

[18] 牛云霞,郑波.Wnt/β-catenin信号通路参与氧化应激的调控以及对造血系统影响的研究进展
[J].中国实验血液学杂志,2025,33(3):927-930.

[19] 汪亚群,刘芳洁,陈惠珍,等.EP4受体激动剂可通过激活Wnt/β-catenin信号途径促进人CD34+细胞体外增殖
[J].中国实验血液学杂志,2017,25(3):656-660.

[20] 王立芳,徐振晔,司海龙,等.双黄升白颗粒对荷瘤鼠化疗骨髓抑制期Wnt信号通路的调控作用
[J].中国中西医结合杂志,2017,37(2):204-208.

引用本文

程玉峰, 郜曦, 郝庆伟, 何蕊, 怀利, 李艳彬, 夏奔, 夏友宏. 益肺扶正解毒法防治肺癌化疗骨髓抑制的临床观察及对Wnt/β-catenin 通路的机制影响 [J]. 国际中医药研究. 2026; 6; (2). 66 - 74.

文献评论

相关学者

相关机构